David Norwood is a founding shareholder in Oxford Pharmascience. David has had a long career building a number of science, technology and investment companies. He is the founder of IP Group plc, one of the UK’s leading technology commercialisation businesses and a shareholder in the Company.
Previously, he was Chief Executive of stockbroker Beeson Gregory (acquired by Evolution Group plc) after it acquired IndexIT Partnership, a technology advisory boutique he had founded in 1999. He was a founding shareholder of Evolution Group plc (recently acquired by Investec), and also co-founder of Ora Capital plc. David has been a founder and/or director of many UK technology companies including Oxford Nanopore, Proximagen, Synairgen, Ilika, Oxford Catalysts and Plectrum Petroleum (acquired by Cairn Energy).
He has also acted as seed investor and/or advisor to Wolfson Microelectronics, Nanoco, Tissue Regenix and Arc International (now part of Synopsys). He is also Chairman of Retroscreen Virology Limited, Europe's leading specialist virology contract research organisation.
Marcelo Bravo is a founder of Oxford Pharmascience and an entrepreneur with a background in chemistry and chemical engineering and international experience with blue-chip companies. Marcelo spent 16 years in R&D with The Procter & Gamble Company and subsequently spent 3 years in corporate development with Boots (now Boots Alliance Plc). After this he became an entrepreneur and most recently was CEO and Board director of Oxford Advanced Surfaces Group Plc, a company he led from inception as a spin-out from Oxford University which is now quoted on the AIM market. Marcelo has extensive experience in developing, launching and growing new products and businesses across a range of both geographic and product markets. Marcelo holds a B.A. in Chemistry from the College of Wooster, USA and a B.Sc. in Chemical Engineering from Case Western Reserve University, USA and an M.Sc in Management from the London Business School.
Chris Hill graduated in Economics and Public Policy in 2001 from Leeds Metropolitan University where he combined his studies with a professional rugby career. He then went on to gain his chartered accountancy qualification with Grant Thornton. Chris is also a director of Quoram Plc, an Investment Company listed on AIM.
James White has extensive experience in operations, product development, regulatory, sales and marketing and general management. James worked for Osmetech Plc for 11 years in a number of senior positions including as Chief Executive for the period 2000 to 2009. Osmetech has operations in the UK and USA and is focused on providing molecular diagnostic technologies through a global sales distribution network. James has a track record of mergers and acquisitions, disposals and fundraising in the UK, USA and Europe and was previously a senior consultant in Arthur D Little's corporate finance practice where he specialised in advising on investments in small and medium sized companies.
John Goddard has had a distinguished career in the global pharmaceutical industry, the majority of which was with AstraZeneca, where he was ultimately Head of Group Strategic Planning and Business Development. Prior to his retirement from AstraZeneca in 2010, he was responsible for a 100 strong global team focused on M&A and licensing, which completed around 75 transactions in four years including several acquisitions, in-licensing and out-licensing of compounds and disposals. Latterly, Mr. Goddard became Chairman of two AstraZeneca subsidiaries, Aptium Oncology in the US and Astratech in Sweden. He is currently a member of the Board of Directors of Optos PLC and IntasPharmaceuticals Limited. Mr Goddard is a Fellow of the Institute of Chartered Accountants and a Member of the Association of Corporate Treasurers.
Karl Van Horn has had a distinguished multinational career in senior positions across investment management, corporate governance, industry and not-for-profit organisations. He has held senior roles in the Trusts and Investments Division of The Morgan Guaranty Trust, American Express Asset Management, the Qatar Investment Board (Doha), J.P. Morgan (Japan) and Aspcomp (Helsinki) amongst other institutional mandates.
Mr. Van Horn is currently the Chairman of the Taube Offshore Fund (Cayman) and a director of American Express Asset Management N.V. (although he has had no active involvement with the latter since 1987). He also is a member of the Investment Management Institute (New York), a Life Trustee of University School (Cleveland, Ohio) and a Trustee of the University of Bologna (Italy). Mr. Van Horn holds a Doctorate in International Affairs from Bologna/Johns Hopkins, a MA in Economics from Cambridge University and a BSc from Yale University. He was formerly a director of Front Row Partners UK LLP.